Sort
30,917 grants matching “tumor microenvironment”
Project 1: Transgenic TCR-mediated tumor therapy
$669,971Philip D Greenberg · University Of Washington · P01 · FY2020 · CA
Quantitative Multimodal Image Guidance for Improved Liver Cancer Treatment
$669,786James S Duncan · Yale University · R01 · FY2016 · CA
DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
$669,747Harrison Kim · University Of Alabama At Birmingham · R01 · FY2024 · CA
Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes
$669,652Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2024 · DK
Cell density effects on therapeutic sensitivity
$669,587Jayne Stommel · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Nuclear Structure and Gene Expression
$669,529Gary S. Stein · Univ Of Massachusetts Med Sch Worcester · P01 · FY2009 · CA
Imaging Modulation of Immune Phenotype
$669,526Katherine W Ferrara · Stanford University · R01 · FY2021 · CA
A Novel Regulator of Antitumor Immunity and Immunotherapy
$669,506Rong Li · George Washington University · R01 · FY2024 · CA
Variation in tumor-associated immune profiles and colorectal cancer outcomes
$669,492Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$669,436Dung T Le · Johns Hopkins University · P01 · FY2021 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$669,436Dung T Le · Johns Hopkins University · P01 · FY2025 · CA
Developing a Translation Pipeline for VHL Mutant Malignancies
$669,180David McDermott · Beth Israel Deaconess Medical Center · U01 · FY2024 · CA
Deciphering the Mechanism of Lymphovascular Space Invasion Using a Lymphovascularized Bioengineering Breast Stromal Platform
$669,122Marissa Nichole Rylander · University Of Texas At Austin · R01 · FY2024 · CA
Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors
$668,910Albert Folch · University Of Washington · R01 · FY2023 · CA
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer
$668,834Lorna Rodriguez-Rodriguez · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Dynamic Imaging of EMT in the Breast Cancer Microenvironment
$668,764Christopher H Contag · Stanford University · R01 · FY2013 · CA
Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture
$668,696Simone Krebs · Sloan-Kettering Inst Can Research · R37 · FY2023 · CA
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$668,650Ming You · Methodist Hospital Research Institute · R01 · FY2022 · CA
Molecular Biomarkers in pathogenesis of Lymphangioleiomyomatosis (LAM)
$668,618Jeanine M D'armiento · Columbia University Health Sciences · R01 · FY2023 · HL
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy
$668,565Kosj Yamoah · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2025 · CA
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
$668,490Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2018 · CA
Human T Cell Responses to Tumor Antigens for Cancer Vaccine Development
$668,432Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Control of the immune response for cancer vaccine development
$668,432Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression
$668,326Dohun Pyeon · Michigan State University · R01 · FY2018 · DE
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer
$668,323Timothy C Thompson · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA